SCHEMBL8129656

SCHEMBL8129656

CC(C)c1ccc(C#C[Si](C)(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.39
ADK P55263 2/20 0.38
GRM5 P41594 2/20 0.36
NOTUM Q6P988 3/20 0.36
TYR P14679 2/20 0.35
FFAR1 O14842 1/20 0.33
HTT P42858 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
ERBB2 P04626 1/20 0.33
NFKB1 P19838 1/20 0.32
NPC1 O15118 1/20 0.32
TP53 P04637 1/20 0.32
RAB9A P51151 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17464783 0.98 ACACB (0.41) ACACBADKGRM5NOTUMTYR
SCHEMBL17464776 0.98 ACACB (0.41) ACACBADKGRM5NOTUMTYR
SCHEMBL30200615 0.83 ADRB2 (0.43) ADKFFAR1GABRA1GABRG2GABRB3
SCHEMBL21673923 0.83 ADRB2 (0.43) ADKFFAR1GABRA1GABRG2GABRB3
SCHEMBL28977400 0.83 NOS3 (0.40) ACACBFFAR1GABRA1GABRG2GABRB3
SCHEMBL23977506 0.83 NOS3 (0.40) ACACBFFAR1GABRA1GABRG2GABRB3
SCHEMBL1306384 0.83 GABRA1 (0.38) GRM5GABRA1GABRG2GABRB3GABRA5
SCHEMBL8141103 0.81 ACACB (0.50) ACACBADKTYRFFAR1HTT
SCHEMBL1306505 0.81 APP (0.41) GRM5GABRA1GABRG2GABRB3GABRA5
SCHEMBL2609821 0.81 ACACB (0.38) ACACBADKGRM5NOTUMTYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150218110-A1 USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2015-08-06 US disclosed
US-20150218110-A1 USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2015-08-06 US disclosed
US-20150216168-A1 USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2015-08-06 US disclosed
US-20150216168-A1 USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2015-08-06 US disclosed
US-7595407-B2 Boron complexation strategy for use in manipulating 1-acyldipyrromethanes NORTH CAROLINA STATE UNIVERSITY (US) 2009-09-29 US disclosed
US-7595407-B2 Boron complexation strategy for use in manipulating 1-acyldipyrromethanes NORTH CAROLINA STATE UNIVERSITY (US) 2009-09-29 US disclosed
US-7423160-B2 Boron complexation strategy for use in manipulating 1-acyldipyrromethanes NORTH CAROLINA STATE UNIVERSITY (US) 2008-09-09 US disclosed
US-20080071093-A1 BORON COMPLEXATION STRATEGY FOR USE IN MANIPULATING 1-ACYLDIPYRROMETHANES LINDSEY JONATHAN S 2008-03-20 US disclosed
US-20080071093-A1 BORON COMPLEXATION STRATEGY FOR USE IN MANIPULATING 1-ACYLDIPYRROMETHANES LINDSEY JONATHAN S 2008-03-20 US disclosed
US-20080027232-A1 BORON COMPLEXATION STRATEGY FOR USE IN MANIPULATING 1-ACYLDIPYRROMETHANES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-01-31 US disclosed
US-7317108-B2 Boron complexation strategy for use in manipulating 1-acyldipyrromethanes NORTH CAROLINA STATE UNIVERSITY (US) 2008-01-08 US disclosed
US-7282582-B2 Boron complexation strategy for use in manipulating 1-acyldipyrromethanes NORTH CAROLINA STATE UNIVERSITY (US) 2007-10-16 US disclosed
US-20070088158-A1 BORON COMPLEXATION STRATEGY FOR USE IN MANIPULATING 1-ACYLDIPYRROMETHANES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-04-19 US disclosed
US-6030969-A ADENOSINE KINASE INHIBITORS; ANTIISCHEMIA,-INFLAMMATORY, -DIABETIC AGENTS; NEUROLOGICAL AND GASTROINTESTINAL DISORDERS; NOCIPERCEPTION, IMMUNOSUPPRESSION; SEPSIS ABBOTT LABORATORIES (US) 2000-02-29 US disclosed
EP-0975633-A1 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL 2,3-D]PYRIMIDINE COMPOUNDS Abbott Laboratories (US) 2000-02-02 EP disclosed
WO-1998046604-A1 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL[2,3-D]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 1998-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088158-A1 BORON COMPLEXATION STRATEGY FOR USE IN MANIPULATING 1-ACYLDIPYRROMETHANES DECR2, ANTXR2, CD79B ACACB 2332/4885ADK 4101/4885GRM5 948/4885
US-20150218110-A1 USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS GABBR1, GABRA1, GABRA6 ACACB 2332/4885ADK 271/4885GRM5 424/4885
US-20080071093-A1 BORON COMPLEXATION STRATEGY FOR USE IN MANIPULATING 1-ACYLDIPYRROMETHANES DECR2, ANTXR2, CD79B ACACB 2332/4885ADK 4101/4885GRM5 948/4885
US-20080027232-A1 BORON COMPLEXATION STRATEGY FOR USE IN MANIPULATING 1-ACYLDIPYRROMETHANES DECR2, ANTXR2, CD79B ACACB 2332/4885ADK 4101/4885GRM5 948/4885
US-20150216168-A1 USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS ABAT, AAK1, AGXT ACACB 406/4885ADK 260/4885GRM5 2867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.